数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Daniel E. Stebbins Director 66 12.89万美元 未持股 2016-03-01
Roger D. Billingsley Director 72 12.34万美元 未持股 2016-03-01
Stephen A. Block Director 71 12.59万美元 未持股 2016-03-01
Michael E. Herman Director 74 12.09万美元 未持股 2016-03-01
Jay M. Short Lead Independent Director 57 13.84万美元 未持股 2016-03-01
Kent Snyder Chairman of the Board 62 13.59万美元 未持股 2016-03-01
Christopher J. Twomey Director 56 13.29万美元 未持股 2016-03-01
John Poyhonen President, Chief Executive Officer and Director 56 157.01万美元 未持股 2016-03-01
Mary Ann Gray Director 63 11.34万美元 未持股 2016-03-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Catherine C. Lee Vice President, General Counsel and Corporate Secretary 42 60.35万美元 未持股 2016-03-01
John Poyhonen President, Chief Executive Officer and Director 56 157.01万美元 未持股 2016-03-01
Sharon Wicker Senior Vice President and Chief Commercial Development Officer 60 78.27万美元 未持股 2016-03-01
Antony E. Rogers Senior Vice President and Chief Financial Officer 49 76.14万美元 未持股 2016-03-01

董事简历

中英对照 |  中文 |  英文
Daniel E. Stebbins

Daniel E. Stebbins,他于2015年9月加入我们董事会。2006年9月以来,他曾一直担任MidOcean Partners的管理成员,并提供行业专业知识,涉及香料、香味和特种化工空间。此外,他曾担任The Stebbins Partnership(为广泛的客户提供管理咨询服务)的总裁(2006年3月以来)。从2002年2月到2004年3月,他曾担任Symrise AG的全球香料部门的总裁。2002年之前,他曾担任Dragoco、GmbH、Dragoco, Inc.的多种高级管理和运营职务。他目前担任Agilex Fragrances的非执行主席、董事。他此前曾任职the Flavor & Extract Manufacturers Association(FEMA)的理事会(1987年至1999年)。他持有Castleton State College的学士学位。


Daniel E. Stebbins joined our Board in September 2015. Since September 2006 Mr. Stebbins has served as Management Affiliate for MidOcean Partners, providing industry expertise in the flavor, fragrance and specialty chemical space. In addition, since March, 2006 he has served as the President of The Stebbins Partnership, which provides management consulting services to a wide range of clients. From February 2002 to March 2004 Mr. Stebbins served as President, Flavor Division Worldwide for Symrise AG. Prior to 2002 Mr. Stebbins held various senior management and operating positions at Dragoco, GmbH and Dragoco, Inc. He currently serves as the Non-executive Chairman and director of Agilex Fragrances. Mr. Stebbins previously served on the Board of Governors of the Flavor & Extract Manufacturers Association, or FEMA, from 1987 to 1999. Mr. Stebbins holds a B.S. from Castleton State College.
Daniel E. Stebbins,他于2015年9月加入我们董事会。2006年9月以来,他曾一直担任MidOcean Partners的管理成员,并提供行业专业知识,涉及香料、香味和特种化工空间。此外,他曾担任The Stebbins Partnership(为广泛的客户提供管理咨询服务)的总裁(2006年3月以来)。从2002年2月到2004年3月,他曾担任Symrise AG的全球香料部门的总裁。2002年之前,他曾担任Dragoco、GmbH、Dragoco, Inc.的多种高级管理和运营职务。他目前担任Agilex Fragrances的非执行主席、董事。他此前曾任职the Flavor & Extract Manufacturers Association(FEMA)的理事会(1987年至1999年)。他持有Castleton State College的学士学位。
Daniel E. Stebbins joined our Board in September 2015. Since September 2006 Mr. Stebbins has served as Management Affiliate for MidOcean Partners, providing industry expertise in the flavor, fragrance and specialty chemical space. In addition, since March, 2006 he has served as the President of The Stebbins Partnership, which provides management consulting services to a wide range of clients. From February 2002 to March 2004 Mr. Stebbins served as President, Flavor Division Worldwide for Symrise AG. Prior to 2002 Mr. Stebbins held various senior management and operating positions at Dragoco, GmbH and Dragoco, Inc. He currently serves as the Non-executive Chairman and director of Agilex Fragrances. Mr. Stebbins previously served on the Board of Governors of the Flavor & Extract Manufacturers Association, or FEMA, from 1987 to 1999. Mr. Stebbins holds a B.S. from Castleton State College.
Roger D. Billingsley

Roger D. Billingsley, Ph.D.,2008年4月以来,他成为Senomyx, Inc.的董事会成员。2008年3月以来,他担任Dole Fresh Vegetables(Dole Food Company的一个部门)的高级副总裁负责技术和产品开发。从2006年6月到2008年3月,他担任 Abbott Nutrition(一个雅培公司(Abbott Laboratories)的部门)的部门副总裁负责研发和科学事务。从2004年9月到2006年6月。他担任Ross Products(雅培公司(Abbott Laboratories)的一个部门)的部门副总裁负责研发和科学事务。2004年之前,他担任ConAgra Foods、Pet Incorporated、Nabisco Brands, Inc和Kellogg Company的高级管理职务。他目前担任Orange County Business Bank的董事。他获得卡本代尔的南伊利诺伊大学(Southern Illinois University )的学士和硕士学位、诺克斯维尔的田纳西大学(the University of Tennessee)的博士学位并完成了在伊利诺伊大学香槟分校( the University of Illinois, Champaign)的博士后研究。


Roger D. Billingsley has served as a member of Senomyx, Inc. Board of Directors since April 2008. From March 2008 to June 2014 Dr. Billingsley served as Senior Vice President, Technology and Product Development of Dole Fresh Vegetables, a division of Dole Food Company. From June 2006 to March 2008 he served as Division Vice President of Research and Development and Scientific Affairs of Abbott Nutrition, a division of Abbott Laboratories, Inc. From September 2004 to June 2006 Dr. Billingsley served as Division Vice President of Research and Development and Scientific Affairs of Ross Products, also a division of Abbott Laboratories, Inc. Prior to 2004 Dr. Billingsley held senior management positions at ConAgra Foods, Pet Incorporated, Nabisco Brands, Inc. and Kellogg Company. Dr. Billingsley currently serves as a director of Orange County Business Bank. Dr. Billingsley holds a B.S. and an M.S. from Southern Illinois University, Carbondale, a Ph.D. from the University of Tennessee, Knoxville and a post-doctoral degree from the University of Illinois at Urbana-Champaign.
Roger D. Billingsley, Ph.D.,2008年4月以来,他成为Senomyx, Inc.的董事会成员。2008年3月以来,他担任Dole Fresh Vegetables(Dole Food Company的一个部门)的高级副总裁负责技术和产品开发。从2006年6月到2008年3月,他担任 Abbott Nutrition(一个雅培公司(Abbott Laboratories)的部门)的部门副总裁负责研发和科学事务。从2004年9月到2006年6月。他担任Ross Products(雅培公司(Abbott Laboratories)的一个部门)的部门副总裁负责研发和科学事务。2004年之前,他担任ConAgra Foods、Pet Incorporated、Nabisco Brands, Inc和Kellogg Company的高级管理职务。他目前担任Orange County Business Bank的董事。他获得卡本代尔的南伊利诺伊大学(Southern Illinois University )的学士和硕士学位、诺克斯维尔的田纳西大学(the University of Tennessee)的博士学位并完成了在伊利诺伊大学香槟分校( the University of Illinois, Champaign)的博士后研究。
Roger D. Billingsley has served as a member of Senomyx, Inc. Board of Directors since April 2008. From March 2008 to June 2014 Dr. Billingsley served as Senior Vice President, Technology and Product Development of Dole Fresh Vegetables, a division of Dole Food Company. From June 2006 to March 2008 he served as Division Vice President of Research and Development and Scientific Affairs of Abbott Nutrition, a division of Abbott Laboratories, Inc. From September 2004 to June 2006 Dr. Billingsley served as Division Vice President of Research and Development and Scientific Affairs of Ross Products, also a division of Abbott Laboratories, Inc. Prior to 2004 Dr. Billingsley held senior management positions at ConAgra Foods, Pet Incorporated, Nabisco Brands, Inc. and Kellogg Company. Dr. Billingsley currently serves as a director of Orange County Business Bank. Dr. Billingsley holds a B.S. and an M.S. from Southern Illinois University, Carbondale, a Ph.D. from the University of Tennessee, Knoxville and a post-doctoral degree from the University of Illinois at Urbana-Champaign.
Stephen A. Block

Stephen A. Block, Esq.,2005年5月以来,他成为我们的董事会成员。从1993年1月到2003年12月退休,他担任International Flavors and Fragrances Inc.(IFF,香精香料的主要创造者,制造商和销售商)的首席法务官(Chief Legal Officer )和秘书。他于2000年2月被任命为IFF的高级副总裁、总法律顾问和秘书。在IFF的年任职期间,他也领导公司的法规事务部门。1993年之前,他担任GAF Corporation(专业从事特种化学品和建筑材料的公司)和Celanese Corporation(专业从事合成纤维、化工和塑料的公司)的各种管理职位,包括高级副总裁、总法律顾问和秘书。他目前担任产业顾问和the Tech Coast Angels(一个领先的天使投资集团)Orange County Network的执行委员会的成员。他是 ChromaDex Corporation(参考标准和原料供应公司)和几个私有公司的董事。他以优异成员获得耶鲁大学(Yale University )的俄语学士学位和哈佛大学法学院( Harvard Law School)的法学学位。


Stephen A. Block,has been a director of the Company since October 2007 and Chair of the Compensation Committee and a member of the Audit Committee since October 2007. From May 2010 to October 2011 Mr. Block served as Lead Independent Director to the Board. Mr. Block is also a director and chair of the nominating and corporate governance committee and a member of the audit committee of Senomyx, Inc. NASDAQ:SNMX, where he has served on the board of directors since 2005. He also is, and since September 2015 has been, a director of myLAB Box, Inc., a privately held company. Until December 2011 he also served as the chairman of the board of directors of Blue Pacific Flavors and Fragrances, Inc., and, until March 2012 as a director of Allylix, Inc. He served on the boards of directors of these privately held companies since 2008 and 2007 respectively. Mr. Block retired as senior vice president, general counsel and secretary of International Flavors and Fragrances Inc., a leading creator, manufacturer and seller of flavors and fragrances (IFF) in December 2003 having been IFF’s chief legal officer since 1992. During his eleven years at IFF he also led the company’s Regulatory Affairs Department. Prior to 1992 Mr. Block served as senior vice president, general counsel, secretary and director of GAF Corporation, a company specializing in specialty chemicals and building materials, and its publicly traded subsidiary International Specialty Products Inc., held various management positions with Celanese Corporation, a company specializing in synthetic fibers, chemicals and plastics, and practiced law with the New York firm of Stroock & Stroock & Lavan. Mr. Block currently serves as an industry consultant and as a Venture Partner of K5 Venture Partners, LLC, an Orange County early stage venture firm. He is also a Managing Director of K5 Venture Partner, LLC’s affiliated accelerator K5 Launch and a member of the executive committee of the Orange County network of Tech Coast Angels, a leading investing group. Mr. Block received his B.A. cum laude in Russian Studies from Yale University and his law degree from Harvard Law School.
Stephen A. Block, Esq.,2005年5月以来,他成为我们的董事会成员。从1993年1月到2003年12月退休,他担任International Flavors and Fragrances Inc.(IFF,香精香料的主要创造者,制造商和销售商)的首席法务官(Chief Legal Officer )和秘书。他于2000年2月被任命为IFF的高级副总裁、总法律顾问和秘书。在IFF的年任职期间,他也领导公司的法规事务部门。1993年之前,他担任GAF Corporation(专业从事特种化学品和建筑材料的公司)和Celanese Corporation(专业从事合成纤维、化工和塑料的公司)的各种管理职位,包括高级副总裁、总法律顾问和秘书。他目前担任产业顾问和the Tech Coast Angels(一个领先的天使投资集团)Orange County Network的执行委员会的成员。他是 ChromaDex Corporation(参考标准和原料供应公司)和几个私有公司的董事。他以优异成员获得耶鲁大学(Yale University )的俄语学士学位和哈佛大学法学院( Harvard Law School)的法学学位。
Stephen A. Block,has been a director of the Company since October 2007 and Chair of the Compensation Committee and a member of the Audit Committee since October 2007. From May 2010 to October 2011 Mr. Block served as Lead Independent Director to the Board. Mr. Block is also a director and chair of the nominating and corporate governance committee and a member of the audit committee of Senomyx, Inc. NASDAQ:SNMX, where he has served on the board of directors since 2005. He also is, and since September 2015 has been, a director of myLAB Box, Inc., a privately held company. Until December 2011 he also served as the chairman of the board of directors of Blue Pacific Flavors and Fragrances, Inc., and, until March 2012 as a director of Allylix, Inc. He served on the boards of directors of these privately held companies since 2008 and 2007 respectively. Mr. Block retired as senior vice president, general counsel and secretary of International Flavors and Fragrances Inc., a leading creator, manufacturer and seller of flavors and fragrances (IFF) in December 2003 having been IFF’s chief legal officer since 1992. During his eleven years at IFF he also led the company’s Regulatory Affairs Department. Prior to 1992 Mr. Block served as senior vice president, general counsel, secretary and director of GAF Corporation, a company specializing in specialty chemicals and building materials, and its publicly traded subsidiary International Specialty Products Inc., held various management positions with Celanese Corporation, a company specializing in synthetic fibers, chemicals and plastics, and practiced law with the New York firm of Stroock & Stroock & Lavan. Mr. Block currently serves as an industry consultant and as a Venture Partner of K5 Venture Partners, LLC, an Orange County early stage venture firm. He is also a Managing Director of K5 Venture Partner, LLC’s affiliated accelerator K5 Launch and a member of the executive committee of the Orange County network of Tech Coast Angels, a leading investing group. Mr. Block received his B.A. cum laude in Russian Studies from Yale University and his law degree from Harvard Law School.
Michael E. Herman

Michael E. Herman,2005年5月以来,他成为我们的董事会成员。2006年以来,他担任the Herman Family Trading Company的总裁。从1992年1月到2000年12月,他曾是 the Kansas City Royals Baseball Club的总裁。从1990年1月到1999年12月,他曾是the Kauffman Foundatio的金融和注资委员会主席。从1985年1月到1990年12月,他是其总裁。从1974年10月到1990年12月,他担任Marion Laboratories的执行副总裁和首席财务官。他是Santarus, Inc.(生物制药公司,2014年被Salix Pharmaceuticals, Ltd.收购)和Cerner Corporation(医疗信息技术公司)的前董事。他也是伦斯勒理工学院(Rensselaer Polytechnic Institute)、芝加哥大学商学院(the University of Chicago Graduate School of Business)和 the Vail Valley Foundation的信托人。他获得伦斯勒理工学院(Rensselaer Polytechnic Institute)的冶金工程学士学位和芝加哥大学(University of Chicago)的工商管理硕士学位。


Michael E. Herman has served as a member of our Board of Directors since May 2005. Since 2006 Mr. Herman has been serving as President of the Herman Family Trading Company. From January 1992 to December 2000 Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999 he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990 Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014 and Cerner Corporation, a health care information technology company, and also is a Trustee of Rensselaer Polytechnic Institute, the University of Chicago Graduate School of Business and the Vail Valley Foundation. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.
Michael E. Herman,2005年5月以来,他成为我们的董事会成员。2006年以来,他担任the Herman Family Trading Company的总裁。从1992年1月到2000年12月,他曾是 the Kansas City Royals Baseball Club的总裁。从1990年1月到1999年12月,他曾是the Kauffman Foundatio的金融和注资委员会主席。从1985年1月到1990年12月,他是其总裁。从1974年10月到1990年12月,他担任Marion Laboratories的执行副总裁和首席财务官。他是Santarus, Inc.(生物制药公司,2014年被Salix Pharmaceuticals, Ltd.收购)和Cerner Corporation(医疗信息技术公司)的前董事。他也是伦斯勒理工学院(Rensselaer Polytechnic Institute)、芝加哥大学商学院(the University of Chicago Graduate School of Business)和 the Vail Valley Foundation的信托人。他获得伦斯勒理工学院(Rensselaer Polytechnic Institute)的冶金工程学士学位和芝加哥大学(University of Chicago)的工商管理硕士学位。
Michael E. Herman has served as a member of our Board of Directors since May 2005. Since 2006 Mr. Herman has been serving as President of the Herman Family Trading Company. From January 1992 to December 2000 Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999 he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990 Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014 and Cerner Corporation, a health care information technology company, and also is a Trustee of Rensselaer Polytechnic Institute, the University of Chicago Graduate School of Business and the Vail Valley Foundation. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.
Jay M. Short

Jay M. Short, Ph.D.,2004年3月以来,他是我们董事会成员。2008年5月以来,他担任我们领导独立董事。2007年3月以来,他担任BioAtla(圣地亚哥和北京的蛋白质疗法研究和开发组织)的主席和首席执行官。此外2011年8月,他从Ciris Energy(专注于煤炭中的生物气体和化学生成的私人生物能源公司)的首席执行官提拔到主席。他是 the E.O.Wilson Biodiversity Foundation(501 c(3)公共慈善机构)的创始人并担任其总裁和主席(从2005年10月其成立到2008年7月)。从1999年2月到2005年10月,他曾是 Diversa Corporation(British Petroleum和BASF的一部分)的总裁和首席执行官。他是Diversa Corporation的创始人并担任公司的首席技术官和董事(从1994年公司成立到2005年10月)。他担任几个民营企业和公司的董事和顾问,包括Ciris Energy、SGB、Genalyte和Thomas McNerney Partners。他还担任Invitrogen Corporation(被Thermo Fisher收购)的董事(1995年到2008年)。2006年作为为过去十年生物技术做出最重要贡献的名人,他曾入围了the editors of Nature Biotechnology。他还担任俄亥俄州克利夫兰的凯斯西储大学(Case Western Reserve University)的生物科学博士学位和印第安纳州高地的泰勒大学(Taylor University)的荣誉化学学士学位。他也参加和获得了加州大学洛杉矶分校(UCLA)安德森商学院(Anderson School of Business)的董事认证证书。


Jay M. Short cofounded BioAtla in March 2007 and has served as Chairman and Chief Executive Officer since that time. He founded the E.O. Wilson Biodiversity Foundation, a public charity, and served as its President and Chairman from its inception in October 2005 through July 2008. From February 1999 to October 2005 Dr. Short was the President and Chief Executive Officer of Diversa Corporation now BASF Corporation, a biotechnology company focusing on enzyme and antibody development which he cofounded. In 1998 he was named President of Diversa, and from 1994 to 2005 he served as Chief Technology Officer. From 1994 to 2008 Dr. Short served as a director of Invitrogen now Life Technologies. From its founding until 1994 Dr. Short served as President of Stratacyte Corporation, an antibody engineering company and subsidiary of Stratagene Cloning Systems, Inc. (now Agilent Technologies, Inc.), a biotechnology company. From 1985 through 1994 he also served in various roles including as Vice President of Research & Development and Operations for Stratagene. In 2006 Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. In 2001 Dr. Short received San Diego’s 2001 E&Y Entrepreneur of the Year Award and was the recipient of the two first place awards granted by UCSD, Connect Innovative Product Program, for pioneering cloning of human antibodies in bacteria and transgenic genotoxicity assay systems. He has authored more than 100 peer reviewed publications and is named inventor of over 500 issued patents. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana. Dr. Short has also attended and received Director Certification from the UCLA Anderson School of Business.
Jay M. Short, Ph.D.,2004年3月以来,他是我们董事会成员。2008年5月以来,他担任我们领导独立董事。2007年3月以来,他担任BioAtla(圣地亚哥和北京的蛋白质疗法研究和开发组织)的主席和首席执行官。此外2011年8月,他从Ciris Energy(专注于煤炭中的生物气体和化学生成的私人生物能源公司)的首席执行官提拔到主席。他是 the E.O.Wilson Biodiversity Foundation(501 c(3)公共慈善机构)的创始人并担任其总裁和主席(从2005年10月其成立到2008年7月)。从1999年2月到2005年10月,他曾是 Diversa Corporation(British Petroleum和BASF的一部分)的总裁和首席执行官。他是Diversa Corporation的创始人并担任公司的首席技术官和董事(从1994年公司成立到2005年10月)。他担任几个民营企业和公司的董事和顾问,包括Ciris Energy、SGB、Genalyte和Thomas McNerney Partners。他还担任Invitrogen Corporation(被Thermo Fisher收购)的董事(1995年到2008年)。2006年作为为过去十年生物技术做出最重要贡献的名人,他曾入围了the editors of Nature Biotechnology。他还担任俄亥俄州克利夫兰的凯斯西储大学(Case Western Reserve University)的生物科学博士学位和印第安纳州高地的泰勒大学(Taylor University)的荣誉化学学士学位。他也参加和获得了加州大学洛杉矶分校(UCLA)安德森商学院(Anderson School of Business)的董事认证证书。
Jay M. Short cofounded BioAtla in March 2007 and has served as Chairman and Chief Executive Officer since that time. He founded the E.O. Wilson Biodiversity Foundation, a public charity, and served as its President and Chairman from its inception in October 2005 through July 2008. From February 1999 to October 2005 Dr. Short was the President and Chief Executive Officer of Diversa Corporation now BASF Corporation, a biotechnology company focusing on enzyme and antibody development which he cofounded. In 1998 he was named President of Diversa, and from 1994 to 2005 he served as Chief Technology Officer. From 1994 to 2008 Dr. Short served as a director of Invitrogen now Life Technologies. From its founding until 1994 Dr. Short served as President of Stratacyte Corporation, an antibody engineering company and subsidiary of Stratagene Cloning Systems, Inc. (now Agilent Technologies, Inc.), a biotechnology company. From 1985 through 1994 he also served in various roles including as Vice President of Research & Development and Operations for Stratagene. In 2006 Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. In 2001 Dr. Short received San Diego’s 2001 E&Y Entrepreneur of the Year Award and was the recipient of the two first place awards granted by UCSD, Connect Innovative Product Program, for pioneering cloning of human antibodies in bacteria and transgenic genotoxicity assay systems. He has authored more than 100 peer reviewed publications and is named inventor of over 500 issued patents. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana. Dr. Short has also attended and received Director Certification from the UCLA Anderson School of Business.
Kent Snyder

Kent Snyder,2003年6月他加入Senomyx。同时,他担任我们董事会成员。2008年5月以来,他担任我们的董事长。从2003年6月到2014年1月,他担任我们的首席执行官。从2003年6月到2009年9月,他担任我们的总裁。从1991年7月到2001年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种市场营销和销售管理职位。他最近担任总裁负责全球商业运营。此前,他担任高级副总裁负责商务协调工作和副总裁负责业务拓展。他是Santarus, Inc.(生物制药公司,2014年被Salix Pharmaceuticals, Ltd.收购)的前董事。他获得堪萨斯大学(the University of Kansas)的学士学位和Rockhurst College的工商管理硕士学位。


Kent Snyder joined Senomyx in June 2003 and has served as a member of our Board of Directors since that time. Since May 2008 Mr. Snyder has served as our Chairman of the Board of Directors. From June 2003 until January 2014 Mr. Snyder served as our Chief Executive Officer, and from June 2003 until September 2009 he served as our President. From July 1991 to October 2001 Mr. Snyder held various marketing and sales management positions with Agouron Pharmaceuticals, Inc., a Pfizer company. Mr. Snyder’s most recent position was President of Global Commercial Operations, and prior to that Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014. Mr. Snyder received his B.S. from the University of Kansas and his M.B.A. from Rockhurst College.
Kent Snyder,2003年6月他加入Senomyx。同时,他担任我们董事会成员。2008年5月以来,他担任我们的董事长。从2003年6月到2014年1月,他担任我们的首席执行官。从2003年6月到2009年9月,他担任我们的总裁。从1991年7月到2001年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种市场营销和销售管理职位。他最近担任总裁负责全球商业运营。此前,他担任高级副总裁负责商务协调工作和副总裁负责业务拓展。他是Santarus, Inc.(生物制药公司,2014年被Salix Pharmaceuticals, Ltd.收购)的前董事。他获得堪萨斯大学(the University of Kansas)的学士学位和Rockhurst College的工商管理硕士学位。
Kent Snyder joined Senomyx in June 2003 and has served as a member of our Board of Directors since that time. Since May 2008 Mr. Snyder has served as our Chairman of the Board of Directors. From June 2003 until January 2014 Mr. Snyder served as our Chief Executive Officer, and from June 2003 until September 2009 he served as our President. From July 1991 to October 2001 Mr. Snyder held various marketing and sales management positions with Agouron Pharmaceuticals, Inc., a Pfizer company. Mr. Snyder’s most recent position was President of Global Commercial Operations, and prior to that Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014. Mr. Snyder received his B.S. from the University of Kansas and his M.B.A. from Rockhurst College.
Christopher J. Twomey

Christopher J. Twomey,2006年3月以来,他成为我们的董事会成员。1990年3月,他加入Biosite Incorporated(医疗诊断公司)担任各种职务并不断被提拔,最后他担任高级副总裁负责财务和首席财务官直到2007年退休。在Biosite时,他负责财务、人力资源、设施和信息系统部门。从1981年到1990年,他在Ernst & Young LLP担任审计经理。2013年8月以来,他担任Tandem Diabetes Care, Inc.(医疗设备公司)的董事和审计委员会主席。他是Cadence Pharmaceuticals, Inc.(专业制药公司,2014年被Mallinckrodt plc收购)的前董事和审计委员会主席。他持有圣巴巴拉市的加州大学(University of California)的学士学位。


Christopher J. Twomey has served as a member of our Board of Directors since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990 Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Since August 2013 Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Mr. Twomey is also a former director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey holds a B.A. from the University of California at Santa Barbara.
Christopher J. Twomey,2006年3月以来,他成为我们的董事会成员。1990年3月,他加入Biosite Incorporated(医疗诊断公司)担任各种职务并不断被提拔,最后他担任高级副总裁负责财务和首席财务官直到2007年退休。在Biosite时,他负责财务、人力资源、设施和信息系统部门。从1981年到1990年,他在Ernst & Young LLP担任审计经理。2013年8月以来,他担任Tandem Diabetes Care, Inc.(医疗设备公司)的董事和审计委员会主席。他是Cadence Pharmaceuticals, Inc.(专业制药公司,2014年被Mallinckrodt plc收购)的前董事和审计委员会主席。他持有圣巴巴拉市的加州大学(University of California)的学士学位。
Christopher J. Twomey has served as a member of our Board of Directors since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990 Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Since August 2013 Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Mr. Twomey is also a former director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey holds a B.A. from the University of California at Santa Barbara.
John Poyhonen

John Poyhonen,2014年1月以来,他一直是我们的首席执行官兼董事会的成员。2009年9月以来,他成为我们的总裁。2003年10月他加入我们并担任副总裁和首席商务官。2004年4月他被任命为副总裁、首席财务官和业务官。2006年1月他被提拔为高级副总裁、首席财务官和业务官。2009年9月他被提拔为总裁和首席运营官。从1996年到2003年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种销售和市场营销职位,最后他担任副总裁负责国际销售,此前他担任副总裁负责市场营销和副总裁负责国民核算。他目前担任Heron Therapeutics, Inc.(专业制药公司)的董事。他在该公司的审计委员会任职并担任其薪酬委员会主席。他获得密歇根州立大学(Michigan State University)的市场营销学士学位和堪萨斯大学(the University of Kansas)的工商管理硕士学位。


John Poyhonen has been our Chief Executive Officer and a member of our Board of Directors since January 2014 and our President since September 2009. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006 he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003 Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.
John Poyhonen,2014年1月以来,他一直是我们的首席执行官兼董事会的成员。2009年9月以来,他成为我们的总裁。2003年10月他加入我们并担任副总裁和首席商务官。2004年4月他被任命为副总裁、首席财务官和业务官。2006年1月他被提拔为高级副总裁、首席财务官和业务官。2009年9月他被提拔为总裁和首席运营官。从1996年到2003年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种销售和市场营销职位,最后他担任副总裁负责国际销售,此前他担任副总裁负责市场营销和副总裁负责国民核算。他目前担任Heron Therapeutics, Inc.(专业制药公司)的董事。他在该公司的审计委员会任职并担任其薪酬委员会主席。他获得密歇根州立大学(Michigan State University)的市场营销学士学位和堪萨斯大学(the University of Kansas)的工商管理硕士学位。
John Poyhonen has been our Chief Executive Officer and a member of our Board of Directors since January 2014 and our President since September 2009. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006 he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003 Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.
Mary Ann Gray

Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来,她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年,Gray博士担任Senomyx Inc.(一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司)的董事会成员。2016年4月至2018年8月,她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月,她担任TetraLogic(一家上市的临床阶段生物制药公司,专注于肿瘤学和传染病)的董事会成员。从2005年到2016年,她还担任Acadia Pharmaceuticals的董事会成员,专注于CNS疗法的商业化。2001年至2016年,她担任罕见病公司Dyax Corp.的董事会成员,该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC(生物技术战略规划和咨询公司)的总裁。她拥有杰出的科学背景,完成了肿瘤生物学的药理学研究,包括治疗对心膜的影响,并开始了她在生物技术领域的职业生涯,作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前,她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位,并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。


Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来,她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年,Gray博士担任Senomyx Inc.(一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司)的董事会成员。2016年4月至2018年8月,她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月,她担任TetraLogic(一家上市的临床阶段生物制药公司,专注于肿瘤学和传染病)的董事会成员。从2005年到2016年,她还担任Acadia Pharmaceuticals的董事会成员,专注于CNS疗法的商业化。2001年至2016年,她担任罕见病公司Dyax Corp.的董事会成员,该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC(生物技术战略规划和咨询公司)的总裁。她拥有杰出的科学背景,完成了肿瘤生物学的药理学研究,包括治疗对心膜的影响,并开始了她在生物技术领域的职业生涯,作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前,她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位,并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.

高管简历

中英对照 |  中文 |  英文
Catherine C. Lee

Catherine C. Lee,2014年5月起,担任本公司的副总裁、法律总顾问、企业秘书。2013年11月到2014年5月,她为一些生命科学公司担任法律顾问。2008年5月至2013年9月,她为一家媒体和娱乐公司Outdoor Channel Holdings, Inc.提供高级管理服务,涉及各自法律事务,最后担任执行副总裁、法律总顾问、企业秘书。2001-2008,她在一家财富500强的能源服务企业Sempra Energy担任过各种法律职务,最后的是企业秘书、法律顾问。加入Sempra Energy之前,她曾在律师事务所Brobeck, Phleger & Harrison LLP、Morrison & Foerster, LLP从事公司和交易法方面的个人执业。她以优异成绩在American University, School of International Service获得国际关系与经济学士学位,在University of Illinois, College of Law获得法律博士学位。


Catherine C. Lee has served as our Vice President, General Counsel and Corporate Secretary since May 2014. From November 2013 to May 2014 Ms. Lee served as a legal consultant for a number of life sciences companies. From May 2008 to September 2013 Ms. Lee advised senior management of Outdoor Channel Holdings, Inc., a media and entertainment company, on a variety of legal matters, where she served most recently as its Executive Vice President, General Counsel and Corporate Secretary. From 2001 to 2008 Ms. Lee held various legal positions at Sempra Energy, a Fortune 500 energy services company, and most recently, as its Corporate Secretary and Counsel. Prior to joining Sempra, Ms. Lee practiced corporate and transactional law at the law firms of Brobeck, Phleger & Harrison LLP and Morrison & Foerster, LLP. Ms. Lee received her B.A. in International Relations and Economics, Magna Cum Laude, from American University, School of International Service, and her J.D. from the University of Illinois, College of Law.
Catherine C. Lee,2014年5月起,担任本公司的副总裁、法律总顾问、企业秘书。2013年11月到2014年5月,她为一些生命科学公司担任法律顾问。2008年5月至2013年9月,她为一家媒体和娱乐公司Outdoor Channel Holdings, Inc.提供高级管理服务,涉及各自法律事务,最后担任执行副总裁、法律总顾问、企业秘书。2001-2008,她在一家财富500强的能源服务企业Sempra Energy担任过各种法律职务,最后的是企业秘书、法律顾问。加入Sempra Energy之前,她曾在律师事务所Brobeck, Phleger & Harrison LLP、Morrison & Foerster, LLP从事公司和交易法方面的个人执业。她以优异成绩在American University, School of International Service获得国际关系与经济学士学位,在University of Illinois, College of Law获得法律博士学位。
Catherine C. Lee has served as our Vice President, General Counsel and Corporate Secretary since May 2014. From November 2013 to May 2014 Ms. Lee served as a legal consultant for a number of life sciences companies. From May 2008 to September 2013 Ms. Lee advised senior management of Outdoor Channel Holdings, Inc., a media and entertainment company, on a variety of legal matters, where she served most recently as its Executive Vice President, General Counsel and Corporate Secretary. From 2001 to 2008 Ms. Lee held various legal positions at Sempra Energy, a Fortune 500 energy services company, and most recently, as its Corporate Secretary and Counsel. Prior to joining Sempra, Ms. Lee practiced corporate and transactional law at the law firms of Brobeck, Phleger & Harrison LLP and Morrison & Foerster, LLP. Ms. Lee received her B.A. in International Relations and Economics, Magna Cum Laude, from American University, School of International Service, and her J.D. from the University of Illinois, College of Law.
John Poyhonen

John Poyhonen,2014年1月以来,他一直是我们的首席执行官兼董事会的成员。2009年9月以来,他成为我们的总裁。2003年10月他加入我们并担任副总裁和首席商务官。2004年4月他被任命为副总裁、首席财务官和业务官。2006年1月他被提拔为高级副总裁、首席财务官和业务官。2009年9月他被提拔为总裁和首席运营官。从1996年到2003年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种销售和市场营销职位,最后他担任副总裁负责国际销售,此前他担任副总裁负责市场营销和副总裁负责国民核算。他目前担任Heron Therapeutics, Inc.(专业制药公司)的董事。他在该公司的审计委员会任职并担任其薪酬委员会主席。他获得密歇根州立大学(Michigan State University)的市场营销学士学位和堪萨斯大学(the University of Kansas)的工商管理硕士学位。


John Poyhonen has been our Chief Executive Officer and a member of our Board of Directors since January 2014 and our President since September 2009. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006 he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003 Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.
John Poyhonen,2014年1月以来,他一直是我们的首席执行官兼董事会的成员。2009年9月以来,他成为我们的总裁。2003年10月他加入我们并担任副总裁和首席商务官。2004年4月他被任命为副总裁、首席财务官和业务官。2006年1月他被提拔为高级副总裁、首席财务官和业务官。2009年9月他被提拔为总裁和首席运营官。从1996年到2003年10月,他担任Agouron Pharmaceuticals, Inc.(一个辉瑞(Pfizer)公司)的各种销售和市场营销职位,最后他担任副总裁负责国际销售,此前他担任副总裁负责市场营销和副总裁负责国民核算。他目前担任Heron Therapeutics, Inc.(专业制药公司)的董事。他在该公司的审计委员会任职并担任其薪酬委员会主席。他获得密歇根州立大学(Michigan State University)的市场营销学士学位和堪萨斯大学(the University of Kansas)的工商管理硕士学位。
John Poyhonen has been our Chief Executive Officer and a member of our Board of Directors since January 2014 and our President since September 2009. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006 he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003 Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.
Sharon Wicker

Sharon Wicker,2009年9月以来,她一直担任我们的高级副总裁兼商业开发总监。从2006年4月她加入Senomyx到2009年9月,她担任我们高级副总裁负责商业发展和首席战略官。从2003年到2006年,她担任各种战略营销职位,最近的A.M. Todd Company的味道业务单元总裁。2003年之前,她担任Heinz、ConAgra和General Mills各种综合管理职位。她获得科罗拉多州立大学(Colorado State University)的食品与营养学学士学位和密歇根州立大学(Michigan State University)的工商管理硕士学位。


Sharon Wicker has served as our Senior Vice President and Chief Commercial Development Officer since September 2009. From when Ms. Wicker joined Senomyx in April 2006 until September 2009 she served as our Senior Vice President of Commercial Development and Chief Strategy Officer. From 2003 to 2006 Ms. Wicker held various strategic marketing positions, most recently as President, Flavor Business Unit, at A.M. Todd Company. Prior to 2003 Ms. Wicker held various general management positions with Heinz, ConAgra and General Mills. Ms. Wicker received her B.S. in Food Science and Nutrition from Colorado State University and her M.B.A. from Michigan State University.
Sharon Wicker,2009年9月以来,她一直担任我们的高级副总裁兼商业开发总监。从2006年4月她加入Senomyx到2009年9月,她担任我们高级副总裁负责商业发展和首席战略官。从2003年到2006年,她担任各种战略营销职位,最近的A.M. Todd Company的味道业务单元总裁。2003年之前,她担任Heinz、ConAgra和General Mills各种综合管理职位。她获得科罗拉多州立大学(Colorado State University)的食品与营养学学士学位和密歇根州立大学(Michigan State University)的工商管理硕士学位。
Sharon Wicker has served as our Senior Vice President and Chief Commercial Development Officer since September 2009. From when Ms. Wicker joined Senomyx in April 2006 until September 2009 she served as our Senior Vice President of Commercial Development and Chief Strategy Officer. From 2003 to 2006 Ms. Wicker held various strategic marketing positions, most recently as President, Flavor Business Unit, at A.M. Todd Company. Prior to 2003 Ms. Wicker held various general management positions with Heinz, ConAgra and General Mills. Ms. Wicker received her B.S. in Food Science and Nutrition from Colorado State University and her M.B.A. from Michigan State University.
Antony E. Rogers

Antony E. Rogers,他是我们高级副总裁和首席财务官。2001年6月他加入我们。加入Senomyx之前,他担任各种职务并不断被提拔。他曾被任命为副总裁负责财务和财务主管(2006年2月)和首席财务官(2009年9月)。2012年1月他被提拔到现在的职务。他之前的经历包括在Indiqu, Inc.、Ancile Pharmaceuticals、Aurora Biosciences和Sequana Therapeutics担任各种财务和会计职务。他获得圣地亚哥州立大学(San Diego State University)的会计学士学位。


Antony E. Rogers Senior Vice President and Chief Financial Officer, joined us in June 2001. Since joining Senomyx he has served in various roles of increasing responsibility and was appointed Vice President, Finance and Treasury in February 2006 Chief Financial Officer in September 2009 and he was promoted to his current position in January 2012. Mr. Rogers received his B.S. in Accounting from San Diego State University.
Antony E. Rogers,他是我们高级副总裁和首席财务官。2001年6月他加入我们。加入Senomyx之前,他担任各种职务并不断被提拔。他曾被任命为副总裁负责财务和财务主管(2006年2月)和首席财务官(2009年9月)。2012年1月他被提拔到现在的职务。他之前的经历包括在Indiqu, Inc.、Ancile Pharmaceuticals、Aurora Biosciences和Sequana Therapeutics担任各种财务和会计职务。他获得圣地亚哥州立大学(San Diego State University)的会计学士学位。
Antony E. Rogers Senior Vice President and Chief Financial Officer, joined us in June 2001. Since joining Senomyx he has served in various roles of increasing responsibility and was appointed Vice President, Finance and Treasury in February 2006 Chief Financial Officer in September 2009 and he was promoted to his current position in January 2012. Mr. Rogers received his B.S. in Accounting from San Diego State University.